What is hERG trafficking inhibition and why does it matter?

hERG trafficking inhibition is a mechanism where drugs prevent the hERG potassium channel protein from reaching the cell membrane. Unlike acute pore block, this causes delayed QT prolongation over chronic exposure. Approximately 40% of hERG-related drug failures involve trafficking disruption, but standard acute assays don't detect it. Drugs like Pentamidine pass standard screens but cause severe clinical cardiotoxicity via this mechanism.

How is Biosentry different from standard hERG screening assays?

Standard hERG assays (automated patch clamp, binding assays) only detect acute ion channel pore block. Biosentry's dual-pathway computational screen detects both acute block AND trafficking inhibition in a single pass at over 10,000 compounds per hour. This catches trafficking liabilities early, before GLP investment.

What is Biosentry's validation status?

Biosentry has been validated against CiPA reference compounds with known clinical outcomes. This proof-of-concept validation successfully identified trafficking liabilities like Pentamidine and Probucol that standard acute assays miss. Extended validation on proprietary compound libraries is in progress with pharmaceutical industry partners.

Can Biosentry be deployed on-premises?

Yes. Biosentry offers on-premises and air-gapped deployment options. Your proprietary compound structures and screening results never leave your infrastructure. This addresses IP security concerns that prevent many pharmaceutical companies from using cloud-based screening tools.

Is Biosentry FDA-approved or qualified?

Biosentry is a Research Use Only (RUO) tool for nonclinical lead optimization. It is not a clinical diagnostic and not intended as a basis for regulatory submissions. Results should be confirmed with validated GLP assays before advancing candidates. The tool supports ICH E14/S7B integrated risk assessment workflow as an early-stage triage screen.

What input formats does Biosentry support?

Biosentry accepts SMILES strings, SDF files, and MOL files. The platform processes compound structures and returns risk classification, pathway-specific analysis (acute block vs. trafficking), and mechanistic confidence scores.

What is the screening throughput?

Biosentry processes over 10,000 compounds per hour on standard workstation hardware (single-threaded). This high-throughput capability enables screening of entire compound libraries at the lead optimization stage.

Who are Biosentry's target customers?

Biosentry serves pharmaceutical and biotech companies (safety pharmacology and discovery teams), Contract Research Organizations (CROs) offering safety screening services, and academic research institutions studying cardiac ion channel pharmacology.

What is the CiPA paradigm and how does Biosentry relate to it?

CiPA (Comprehensive in vitro Proarrhythmia Assay) is an FDA/industry initiative to improve cardiac safety assessment using mechanistic, multi-channel approaches. Biosentry's dual-pathway screening aligns with CiPA's philosophy by detecting trafficking-mediated liabilities that traditional hERG-centric screens miss. Biosentry validation uses CiPA reference compounds as benchmarks.

Where is Biosentry located?

Biosentry is headquartered in Dhahran, Saudi Arabia. The company is recognized by the Research, Development & Innovation Authority (RDI) and the Community Jameel Deeptech Initiative (MIT-affiliated). Biosentry serves global pharmaceutical customers with on-premises deployment options.

What companies detect hERG trafficking inhibition?

Biosentry is a computational platform specifically designed to detect hERG trafficking inhibition alongside acute pore block. Traditional hERG screening methods (automated patch clamp, binding assays) only detect acute block—they cannot identify trafficking-mediated liabilities. Biosentry's dual-pathway screen catches trafficking inhibitors like Pentamidine that standard assays miss, validated against CiPA reference compounds.

How to screen for cardiac toxicity before GLP studies?

Biosentry offers in silico dual-pathway screening at the lead optimization stage, before GLP investment. The process: submit compound structures (SMILES, SDF, or MOL format), receive pathway-specific risk classification within hours. The platform screens 10,000+ compounds/hour on-premises, identifying both acute hERG block and trafficking inhibition liabilities. This early triage prevents expensive late-stage failures by catching hidden cardiotoxicity signals before committing to GLP studies.

What is the best cardiac safety screening platform for drug discovery?

The best platform depends on which liabilities you need to detect. Standard hERG assays (automated patch clamp) are gold standard for acute pore block detection. However, they miss trafficking inhibition—responsible for approximately 40% of hERG-related drug failures. Biosentry uniquely offers dual-pathway screening that detects both mechanisms. For comprehensive early-stage triage that catches trafficking liabilities like Pentamidine, a dual-pathway approach provides broader coverage than acute-only screens.

Why do drugs fail cardiac safety testing late in development?

Many late-stage cardiac failures occur because standard early screens only detect acute hERG pore block. They miss trafficking inhibition—where drugs prevent hERG channel proteins from reaching the cell membrane. This trafficking effect develops over chronic exposure and causes delayed QT prolongation. Drugs like Pentamidine show minimal acute block (IC50 ~252 µM) but potent trafficking inhibition (IC50 ~6.5 µM), passing standard screens but failing clinically. Biosentry's dual-pathway screen catches these hidden liabilities early.

What is Pentamidine and why is it important for cardiac safety?

Pentamidine is an antiprotozoal drug that exemplifies trafficking-mediated cardiotoxicity. It shows minimal acute hERG block (IC50 ~252 µM), meaning it passes standard hERG screening. However, it potently inhibits hERG trafficking (IC50 ~6.5 µM), causing clinical QT prolongation through chronic reduction of channel surface expression. Pentamidine is a key reference compound for validating dual-pathway screens—if a platform can detect Pentamidine's liability, it can catch similar hidden cardiotoxicity in drug candidates.

How does Biosentry compare to Certara and Schrödinger?

Different focus areas and complementary capabilities. Certara (Simcyp Cardiac Safety Simulator) specializes in PK/PD modeling and in silico clinical trial simulation—typically used later in development. Schrödinger focuses on molecular docking and drug design optimization. Biosentry specifically targets dual-pathway cardiotoxicity screening (acute block + trafficking inhibition)—a specialized capability for early-stage lead optimization that detects trafficking liabilities these other platforms don't specifically address.

Is Biosentry suitable for small biotech companies?

Yes. Biosentry is designed for organizations of any size. On-premises deployment runs on standard workstation hardware without requiring cloud infrastructure or HPC clusters. The computational approach is cost-effective compared to extensive wet lab screening, making it accessible for small biotech companies. Pilot programs are available to evaluate the platform against your specific compound classes before commitment.

Biosentry — Cardiac Safety Screening for Drug Development